ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
First Patient Dosed in DUR-928 Study in COVID-19 Patients with Acute Liver, Kidney Injury
September 30, 2020DURECT has dosed the first patient in its randomized, double-blind, placebo-controlled, multi-center Phase 2 study to evaluate the safety and efficacy of DUR-928 in hospitalized COVID-19 patients with acute liver or kidney injury. -
SeaStar to Study Selective Cytopheretic Device in COVID-19 Patients with ARDS, Kidney Injury
May 04, 2020SeaStar Medical has received approval of their Investigational Device Exemption (IDE) supplement from the U.S. Food and Drug Administration (FDA) to initiate a feasibility, compassionate use study.
Pharma Sources Insight January 2025
